COVID-19: Covaxin gets approval for phase 2-3 clinical trials for 2-18 age group, to begin in next 10-12 days

COVID-19: Covaxin gets approval for phase 2-3 clinical trials for 2-18 age group, to begin in next 10-12 days

DNA

Published

Phase 2-3 clinical trials of Covaxin, which has been approved by the DCGI for in the age group of 2 to 18 years, will begin in 10 to 12 days.

Full Article